Our Financial Analysts Break Down our Top Three Emerging Stocks – MindMed (MMED.NE) vs. Field Trip (FTRP.CN) vs. Cybin (CYBN.NE)
There has been a lot of noise around listed psychedelic investment opportunities of late. Over the past six months, we’ve seen a handful of psychedelic companies listing in Canada across stock exchanges such as the TSX-V, CSE, and NEO. Now, we’ll take a closer look at three of them; Cybin, MindMed, and Field Trip Health, to see how they rank against each other.
Company Focus: Psychedelic Drug Development for MMED Stock, CYBN Stock
In terms of company focus, MindMed currently has two main drug development programs: one is based on a derivative of the hallucinogenic root ibogaine, while the other, titled Project Lucy, is focused on the potential medicinal uses of the lysergic acid diethylamide (LSD). They also recently launched their digital medicine division, Albert.
Field Trip Health on the other hand is focusing its efforts on providing treatments that guide patients through ketamine-enhanced psychotherapy (“KEP”). At the moment, ketamine is the only legal psychedelic medicine available for prescription by health care practitioners in Canada and the U.S.
Cybin is looking to develop psychedelic and non-psychedelic products. Its pharmaceutical segment (psychedelic) is developing micro-dose psilocybin to treat depression, PTSD, addiction and eating disorders. Within the nutraceutical segment (non-psychedelic), Cybin is looking to commercialize a comprehensive line of functional mushroom adaptogens.
Pre-IPO Funding: Institutional Investment
Prior to listing in October 2020, Field Trip successfully completed two rounds of funding. Its first Series-A round in February 2020 saw it raise $8.5mm led by its founders and Singhal Health Foundation. Its second round in August 2020 brought in $11.0mm. The funds were used for establishing a network of medical centres focused exclusively on psychedelic-enhanced psychotherapy, and to help fund the final construction of its research and cultivation facility at the University of the West Indies in Jamaica.
Cybin managed to raise a total of ~$45mm before its IPO debut. Out of this, ~$35mm was raised through a private placement offering in October 2020 (largest subscription receipt financing in the Canadian psychedelic sector). The primary use of the funds was to progress its psychedelic therapies and nutraceutical product development phase.
Mindmed raised a total of $30.0mm before its IPO debut in early March 2020. Since then, through 2 post-IPO financing rounds, it managed to raise another $32.0mm from institutional investors. It is currently in the process of raising another $30.0mm through a bought deal offering. These proceeds will help in progressing its clinical trial pipeline of psychedelic inspired medicines and experiential therapies.
Management Team & Advisory Board
Field Trip Health is led by a management team with deep expertise in healthcare & biotechnology. Its management team has experience working with companies such as Aurora Cannabis, Trait Biosciences, Acerus Pharmaceuticals & Cynapsus Therapeutics.
Further, its Advisory Board members have experience in various pharma & biotechnology companies such as Bayer Pharmaceuticals, Sanofi, Proteosis Therapeutics, and BioTherapeutics, among others.
Cybin’s management team have many years of professional experience working across a host of pharmaceutical and healthcare brands such as Pernix Therapeutics, Biovail Pharmaceuticals and Eli Lilly to name a few.
It’s Advisory Board members have also served in executive positions at numerous pharmaceutical and healthcare giants such as Teva & Baxter Healthcare, as well as leading research organizations including the Canadian Centre for Psychedelic Science and the Canadian Generic Pharmaceutical Association.
Mindmed also boasts an extremely qualified and proficient management team with relevant sector expertise. It’s management and advisory team has experience working in companies such as Merck, Roche, Actelion Pharmaceuticals, Canopy Growth Corporation, and Miramar Labs to name a few. The Company constantly collaborates with professors and doctors from leading institutions such as the John Hopkins Center for Psychedelic and Consciousness Research.
Stock Trading Summary
Apart from the CSE, MindMed also trades on the Frankfurt Stock Exchange under the ticker “MMQ” as well as the U.S. OTC market under the ticker “MMEDF”.
Field Trip Health and Cybin also trade on the U.S. OTC market under the tickers “FTRPF” & “CLXPF”, respectively.
TICKERS: FieldTrip FTRP.CN, Cybin Inc (CYBN.NE), MindMed (MMED.NE)
Field Trip & MindMed have seen a strong price appreciation since listing. MindMed, which has been trading on the markets for about 8 months now, has seen a whopping 546% increase from its listing price to date. Its meteoric rise can be attributed in part to the fact that it was the first listed psychedelics company. Hence, investors who were eagerly waiting on the side-lines for exposure to this sector rushed in upon its listing.
Field Trip shares have risen 66% since listing in early October, showcasing strong investor appetite. The Markets’ response to Cybin’s listing has also been encouraging with the stock currently up 51% from listing.
All 3 stocks have a high free float % which makes them liquid securities to trade in. MindMed is by far the largest of the 3 players with a market cap of over $650mm. Field Trip and Cybin are roughly one fifth the size with market caps of $130mm and $144mm, respectively.
Psychedelic Financials & Cash Balance
Though each of the three companies have started recording revenues, all of them are presently loss-making. As per the latest quarterly filings, Field Trip, Cybin & MindMed had total cash balances of $14.0mm, +$45.0mm, and $24.1mm, respectively. Cybin has the largest war-chest, giving them a lot of room for strategic acquisitions and runway as they go through a drug development roadmap.
In fact, on December 7th, 2020, Cybin announced its acquisition of Adelia Therapeutics for ~$15.75mm. The acquisition adds an extensive intellectual property portfolio and helps Cybin diversify its programs.
At the moment, Field Trip Health & Cybin do not have any broker coverage. We usually see initiating broker coverage once the stock has been trading on the exchange for at least a quarter. On the other hand, MindMed currently has two analysts covering the stock, both with a ‘Strong Buy’ recommendation. This indicates both Cybin and Field Trip may have some strong buying signals from analysts in the coming month.
Given that the psychedelics space is currently witnessing new entrants almost every month, investors need to do their due diligence before investing. Each of the 3 stocks we highlighted above are focused on different psychoactive compounds. There is no doubt that investor interest for these stocks will continue to rise going forward. However, it is important to keep track of corporate developments and management guidance from time to time to ensure that the company’s progress stays on track. Those able to identify these trends early on will see immense capital appreciation in their investments.
Disclaimer: Nothing contained in this article is intended to be, nor shall it be construed as, investment advice by Truffle Report, the parent company or any of its affiliates, nor is it to be relied upon in making any investment or other decision. Neither the information nor any opinion expressed on this email constitutes and offer to buy or sell any security or instrument or participate in any particular trading strategy. The information on the site is not a complete description of the securities, markets or developments discussed. Information and opinions regarding individual securities do not mean that a security is recommended or suitable for a particular investor. Prior to making any investment decision, you are advised to consult with your broker, investment advisor or other appropriate tax or financial professional to determine the suitability of any investment.
Opinions and estimates expressed on this site constitute Truffle Report’s judgment as of the date appearing on the opinion or estimate and are subject to change without notice. This information may not reflect events occurring after the date or time of publication. Truffle Report is not obligated to continue to offer information or opinions regarding any security, instrument or service.
Information has been obtained from sources considered reliable, but its accuracy and completeness are not guaranteed. Truffle Report and its officers, directors, employees, agents and/or affiliates may have executed, or may in the future execute, transactions in any of the securities or derivatives of any securities discussed on this email.
Past performance is not necessarily a guide to future performance and is no guarantee of future results. Securities products are not FDIC insured, are not guaranteed by any bank and involve investment risk, including possible loss of entire value. Truffle Report shall not be responsible or have any liability for investment decisions based upon, or the results obtained from, the information provided.
Truffle Report is not responsible for the content of other emails to which this one may be linked and reserves the right to remove such links.